| Species |
Human |
| Protein Construction |
| HA |
ST3GAL4 (Glu41-Phe333)_x000D_
Accession # Q11206.1 |
His |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
35.4 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 48-53 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
ST3GAL4 gene expression is altered in different cancer types, including cervical cancer. Several mRNA transcripts have been reported for this gene. ST3GAL4 encodes for β‑galactosidase α‑2,3‑sialyltransferase 4, involved in the biosynthesis of the tumour antigens sLe(x) and sulfo‑sLe(x). |
| Synonyms |
SIAT4; SIAT4C; ST3GAL4; ST3GalA.2; ST-4; STZSIAT4; CGS23; Gal-NAc 6S; NANTA3; SAT3; SAT-3 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
